|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Select publications Berry DA et al. Effects of improvements in chemotherapy on disease-free and overall survival of estrogen-receptor negative, node-positive breast cancer: 20-year experience of the CALGB & US Breast Intergroup. Breast Cancer Res Treat 2004;88(Suppl 1):A-29. Abstract Burnell M et al. A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of an interim analysis. San Antonio Breast Cancer Symposium 2006;Abstract 53. Fisher B et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001a;93(9):684-90. Abstract Fisher B et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results of the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990:8(9):1483-96. Abstract Goldstein L et al. E2197: Phase III AT (doxorubicin/docetaxel) vs AC (doxorubicin/ cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. Proc ASCO 2005;Abstract 512. Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41. Jones SE et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24(34):5381-7. Abstract Jones SE et al. Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 40. Liu R et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. New Engl J Med 2007;356(3):217-26. Abstract Martin M et al; Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract Paik S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24(23):3726-34. Abstract Paik S et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92(24):1991-8. Abstract Sparano J. The TAILORx trial: Individualized options for treatment. Community Oncology 2006;3(8):494-9. No abstract available Stockler MR et al. A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment. San Antonio Breast Cancer Symposium 2006;Abstract 6066. Venturini M et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial. J Natl Cancer Inst 2005;97(23):1724-33. Abstract
|
|
